57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial. - Yap, Y-S.; Im, S-A.; Lu, Y-S.; Azim, H.A.; Eralp, Y.; Kanakasetty, G.B.; Abdel-Razeq, H.; Zhukova, L.; Thuerigen, A.; Delgar Alfaro, T.; Wu, J.; Gao, M.; et al. (Annals of Oncology, 2023)